Observational study of cenegermin for the treatment of limbal stem cell deficiency associated with neurotrophic keratopathy
Background: Neurotrophic keratopathy (NK) and limbal stem cell deficiency (LSCD) have high morbidity and require aggressive management to prevent permanent vision loss. Cenegermin, a recombinant human nerve growth factor, was approved by the Federal Drug Administration in 2018 for the treatment of N...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-11-01
|
| Series: | Therapeutic Advances in Ophthalmology |
| Online Access: | https://doi.org/10.1177/25158414221134598 |